Search filters

List of works by Howard L. Kaufman

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

scientific article (publication date: November 2016)

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

scientific article published oln 16 November 2016

A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer

scientific article

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma

scientific article published on 20 September 2016

Activation of Rho kinase by TNF-alpha is required for JNK activation in human pulmonary microvascular endothelial cells.

scientific article published in January 2008

Acute viral infection results in a PD-1-dependent loss of anti-tumor CD8+ T cell responses: implications for tumor immunotherapy.

scientific article published on 4 November 2015

An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions

scientific article published on 07 August 2020

An update on TroVax for the treatment of progressive castration-resistant prostate cancer

scientific article

Author Correction: Integrating oncolytic viruses in combination cancer immunotherapy

scientific article published on 01 August 2018

Avelumab and other recent advances in Merkel cell carcinoma

scientific article published on 4 October 2017

Biomarkers for Immunotherapy: Current Developments and Challenges

scientific article published in January 2016

Chemokines and cancer.

scientific article

Clinical benefit of high dose IL-2 (HD IL-2) therapy: evidence for improved overall survival in patients with stable disease

scientific article published on 7 November 2013

Clinical protocol. Intra-Lesional rF-B7.1 versus rF-TRICOM vaccine in the treatment of metastatic cancer

Combination Immunotherapy for Melanoma

scientific article published on 01 June 2015

Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer

scientific article

Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival

scientific article published on 7 November 2013

Combination immunotherapy with anti-CTLA-4 and interleukin-2 redirects regulatory T cells into tumor-draining lymph nodes and expands anti-tumor CD8+ T cells in the tumor microenvironment

scientific article published on 6 November 2014

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

scientific article published on 06 October 2016

Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma

scientific article

Cytokine therapy for cancer

scientific article published on 01 October 2007

Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1

scientific article published on 10 August 2019

Discovery and clinical introduction of first-in-class imipridone ONC201.

scientific article published on September 2016

Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment

scientific article published on 13 March 2018

Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2).

scientific article published on 4 November 2015

Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma

scientific article published on 4 November 2015

Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis

scientific article published on 21 August 2018

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma

scientific article published on 06 June 2019

Finding gold in tumour immunotherapy.

scientific article

First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors.

scientific article published on 22 March 2017

Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".

scientific article published on 3 June 2013

Gene therapy for antitumor vaccination

scientific article

Gene therapy with poxvirus vectors.

scientific article

HIV infection accelerates gastrointestinal tumor outgrowth in NSG-HuPBL mice

scientific article published on 3 April 2014

High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014

scientific article published on 16 September 2014

High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates

scientific article published on 7 November 2013

High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma

scientific article published on 01 January 2019

High-dose IL-2 induces rapid albumin uptake by endothelial cells through Src-dependent caveolae-mediated endocytosis

scientific article published on 25 June 2014

Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand

scientific article published on 20 October 2009

IFN-λ cancer immunotherapy: new kid on the block

scientific article

Immune properties of recombinant vaccinia virus encoding CD154 (CD40L) are determined by expression of virally encoded CD40L and the presence of CD40L protein in viral particles

scientific article published in December 2004

Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses

scientific article

Immunotherapy for melanoma

scientific article published on 01 May 2004

Immunotherapy for pancreatic cancer: current concepts

scientific article

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry

scientific article

Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin 2

scientific article published on 04 April 2005

Integrating oncolytic viruses in combination cancer immunotherapy

scientific article published on 01 August 2018

Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells.

scientific article

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy

scientific article published on 20 September 2016

Intrarectal vaccination with recombinant vaccinia virus expressing carcinoembronic antigen induces mucosal and systemic immunity and prevents progression of colorectal cancer

scientific article published in December 2008

Intratumoral Approaches for the Treatment of Melanoma

scientific article published on January 2017

Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer

scientific article published on 30 December 2019

Leiomyoma of the breast

scientific article published on 01 May 1996

Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment

scientific article

Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma

scientific article published on 01 March 2010

Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors

scientific article

Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma.

scientific article published on 18 October 2016

MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation

scientific article published on 01 December 2018

MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients.

scientific article

Management of metastatic malignant melanoma of the bladder

scientific article published on 01 August 2003

Management of metastatic melanoma to the breast with high-dose interleukin-2 and surgical resection

scientific article published on 01 March 2005

Melanoma as a model for precision medicine in oncology.

scientific article

Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy

scientific article published on 30 December 2015

Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma

scientific article published on 04 April 2019

Mutant HSP70 reverses autoimmune depigmentation in vitiligo

scientific article published on February 2013

NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade.

scientific article published on 19 May 2015

Non-oncogenic Acute Viral Infections Disrupt Anti-cancer Responses and Lead to Accelerated Cancer-Specific Host Death.

scientific article

OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma

scientific article published on June 2010

Oncolytic Immunotherapy

scientific article published on 05 April 2019

Oncolytic virus immunotherapy for melanoma

scientific article published on March 2015

Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma

scientific article published on 07 April 2019

Oncolytic virus therapy for cancer

scientific article

Oncolytic viruses: a new class of immunotherapy drugs

scientific article published on September 2015

Oncolytic viruses: a new class of immunotherapy drugs

scientific article published on 01 August 2016

Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2.

scientific article published on 4 November 2015

Panniculitis after vaccination against CEA and MUC1 in a patient with pancreatic cancer

scientific article published on 01 January 2005

Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma

scientific article published on 02 November 2009

Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma

scientific article published on 07 January 2009

Pox viral vaccine approaches.

scientific article

Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer

scientific article

Poxviruses as vectors for cancer immunotherapy.

scientific article

Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines.

scientific article

Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory molecules

scientific article

Role of dose selection in successful interleukin-2 immunotherapy: solving the Goldilock’s Complex

scientific article published on 7 November 2013

Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy

scientific article

Small bowel obstruction by jejunal enterolith

scientific article published on 01 February 1997

Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2.

scientific article published on 6 November 2014

Surgical Management of Melanoma

scientific article

Surgical treatment of stage IV melanoma.

scientific article published in May 2004

Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma

scientific article published on 17 December 2016

Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma

scientific article

The contralateral sentinel node.

scientific article published on October 2005

The impact of age on a mitoxantrone-based tumor vaccine

scientific article published on 7 November 2013

The lymphoid chemokine CCL21 costimulates naive T cell expansion and Th1 polarization of non-regulatory CD4+ T cells

scientific article published on 01 September 2004

The role of surgery following incomplete response to high-dose IL-2 (HD IL-2).

scientific article published on 7 November 2013

The tumour microenvironment and implications for cancer immunotherapy

scientific article published on July 2006

Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide

scientific article

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade

scientific article published on 03 February 2019

TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: Lessons learned and future development ⬇️

scientific article published on October 1, 2010

Trovax ® Vaccine Therapy for Renal Cell Carcinoma ⬇️

scientific article published on January 1, 2012

Two roads for oncolytic immunotherapy development

article

Unleashing the therapeutic potential of oncolytic viruses

scientific article published on 5 March 2018

Vaccines for Melanoma and Renal Cell Carcinoma ⬇️

scientific article published on June 1, 2012

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma

scientific article

Paulina is supported by:

About Paulina

Help